Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What Is the Estimated Industry Valuation for the Gabapentin Sector?

The market size of gabapentin has seen robust growth over the past few years. It is projected to expand from $2.78 billion in 2024 to $3.01 billion in 2025, with a compound annual growth rate (CAGR) of 8.5%. Factors contributing to the growth during the historic period include a rise in epilepsy cases, increasing occurrences of neuropathic pain, heightened awareness of neurological disorders, a growing elderly population, and increased usage of generic anticonvulsants.

In the forthcoming years, the gabapentin market is projected to witness substantial growth, eventually reaching $4.12 billion by 2029 with a Compound Annual Growth Rate (CAGR) of 8.2%. Factors contributing to this growth in the projection period include a growing demand for chronic pain management, increased acceptance of gabapentin compounds, expanded healthcare access in emerging areas, a heightened emphasis on individualized medicine, and an increasing burden of neurological disorders. Dominant trends for the projection period encompass advancements in drug delivery mechanisms, the utilization of gabapentin in integrated therapies, technology-driven neuropathic pain research and development, progress in extended-release formulations, and advancements in the application of pharmacogenomics.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24544&type=smp

What Forces Are Driving The Growth Of The Gabapentin Market?

The gabapentin market’s upward trajectory is attributable to the growing incidence of epilepsy. This brain condition, marked by recurring seizures induced by irregular brain electrical activity, is primarily increasing due to the expanding aging population, as the risk of neurological disorders causing seizures tends to rise with age. Gabapentin manages epilepsy by curbing unusual nerve activity in the brain and diminishing signals that trigger seizures. It operates by focusing on calcium channels to stave off seizure onset. For instance, the Centers for Disease Control and Prevention, a government agency based in the U.S., revealed in May 2024 that approximately 2.9 million U.S. adults aged 18 and above reported having active epilepsy in 2022, marking a 1.08% rise from 2021. Thus, the escalating presence of epilepsy is propelling gabapentin market growth.

How Is The Gabapentin Industry Segmented Across Key Parameters?

The gabapentin market covered in this report is segmented –

1) By Type: Generic, Branded

2) By Dosage Form: Tablet, Capsule, Oral Solution

3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Other Distribution Channels

4) By Application: Epilepsy, Neuropathic Pain, Restless Legs Syndrome, Other Applications

Subsegments:

1) By Generic: Gabapentin Immediate Release (IR), Gabapentin Extended Release (ER), Gabapentin Capsules, Gabapentin Tablets, Gabapentin Oral Solution

2) By Branded: Neurontin, Gralise, Horizant, Other Branded Formulations

What Notable Trends Are Shaping The Direction Of The Gabapentin Market?

Key players in the gabapentin market are concentrating on the creation of superior formulas, like bioequivalent tablets, with aims to improve therapeutic efficacy and broaden the spectrum of treatments available for neurological disorders. Generic drugs like bioequivalent tablets release the same dosage of the active component in the bloodstream, at similar rates and efficiency as their branded counterparts, thus ensuring comparable safety and therapeutic impact. For instance, in March 2024, Strides Pharma Science Limited – a pharmaceutical corporation based in India, launched Gabapentin Tablets USP with strengths of 600 mg and 800 mg. This product line, which obtained approval from the United States Food & Drug Administration (USFDA), was designed to enlarge the company’s neurology range in the US market. This novel gabapentin proffers heightened bioavailability, accurate dosage, and user-friendly application, thus allowing for more consistent treatment results, enhanced symptom management, and added convenience for prolonged therapy. Gabapentin tablets USP, 600 mg, provide a versatile therapeutic utility, enabling efficient treatment of various brain conditions like neuropathic pain and partial seizures by means of dependable dosage and demonstrated clinical efficacy.

Which Companies Currently Dominate The Competitive Landscape In The Gabapentin Industry?

Major companies operating in the gabapentin market are Pfizer Inc., Teva Pharmaceutical Industries Ltd., Mylan Inc., Apotex Inc., Sun Pharmaceutical Industries Ltd., Aurobindo Pharma Limited, Cipla Limited, Lupin Limited, Zydus Lifesciences Limited, Glenmark Pharmaceuticals Limited, Torrent Pharmaceuticals Ltd., Ipca Laboratories Private Limited, Granules India Limited, Medley Pharmaceuticals Limited, Wockhardt Limited, Epic Pharma LLC, Healing Pharma India Pvt. Ltd., Rochem International Inc., Accord Healthcare Limited, Strides Pharma Science Limited, Ascend Laboratories LLC

Get The Full Report Here:

https://www.thebusinessresearchcompany.com/report/gabapentin-global-market-report

Which Geographic Regions Are Driving Demand In The Gabapentin Market?

North America was the largest region in the gabapentin market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the gabapentin market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=24544&type=smp

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model